Medicine and Health Sciences Commons^™

The Mixed Lineage Kinase-3 Inhibitor Urmc-099 Improves Therapeutic Outcomes For Long-Acting Antiretroviral Therapy., Gang Zhang, Dongwei Guo, Prasanta Dash, Mariluz Araínga, Jayme Wiederin, Nicole A. Haverland, Jaclyn Knibbe-Hollinger, Andrea Martinez-Skinner, Pawel Ciborowski, Val S. Goodfellow, Tadeusz A. Wysocki, Beata J. Wysocki, Larisa Y. Poluektova, Xin-Ming Liu, Joellyn Mcmillan, Santhi Gorantla, Harris A. Gelbard, Howard Gendelman

Journal Articles: Pharmacology & Experimental Neuroscience

During studies to extend the half-life of crystalline nanoformulated antiretroviral therapy (nanoART) the mixed lineage kinase-3 inhibitor URMC-099, developed as an adjunctive neuroprotective agent was shown to facilitate antiviral responses. Long-acting ritonavir-boosted atazanavir (nanoATV/r) nanoformulations co-administered with URMC-099 reduced viral load and the numbers of HIV-1 infected CD4+ T-cells in lymphoid tissues more than either drug alone in infected humanized NOD/SCID/IL2Rγc-/- mice. The drug effects were associated with sustained ART depots. Proteomics analyses demonstrated that the antiretroviral responses were linked to affected phagolysosomal storage pathways leading to sequestration of nanoATV/r in Rab-associated recycling and late endosomes; sites associated with viral …